Tesamorelin Research Peptide — Scientific Overview
Tesamorelin is a synthetic GHRH analog developed by Theratechnologies Inc. that incorporates a trans-3-hexenoic acid modification at the N-terminus of the full 44-amino-acid GHRH sequence. This N-terminal modification protects the peptide from DPP-IV cleavage at position 2, significantly extending its plasma stability while preserving the complete GHRH receptor-binding sequence. Unlike other GHRH analogs that use the shorter 29-amino-acid fragment, Tesamorelin retains the complete 44-amino-acid GHRH sequence, which may contribute to its pharmacological profile.
Tesamorelin is the only GHRH analog to have received FDA approval for any indication. It was approved in 2010 under the brand name Egrifta (Theratechnologies) for the reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients on antiretroviral therapy — a metabolic complication characterized by pathological visceral fat accumulation. This regulatory approval and extensive Phase III clinical data make Tesamorelin one of the most comprehensively characterized GHRH analogs for research purposes.
Research Background
The Phase III clinical data for Tesamorelin in HIV lipodystrophy documented significant reductions in visceral adipose tissue (VAT) measured by CT scan, improvements in triglyceride levels, and quality-of-life improvements in HIV-infected subjects. Research has also examined Tesamorelin’s effects on cognitive function in HIV-associated neurocognitive disorder and in normal aging, with published randomized trials by Baker et al. and others showing cognitive benefits in memory performance.
Key Research Areas
- Metabolic Research: Visceral adipose tissue reduction and lipid metabolism studies
- GH Axis Research: Full-length GHRH analog pharmacology and IGF-1 axis studies
- HIV Research: Lipodystrophy biology and antiretroviral-associated metabolic complications
- Cognitive Research: GH/IGF-1 axis effects on cognitive function in aging and disease models
- Body Composition Research: CT-measured visceral fat, lean mass, and metabolic parameter studies
- Regulatory Science: FDA-approved GHRH analog as clinical research reference compound
Technical Specifications
| Parameter |
Value |
| Classification |
Full-length GHRH analog (44 AA + trans-3-hexenoic acid N-terminal modification) |
| Molecular Weight |
~5195 Da |
| Purity |
≥98% (HPLC-verified) |
| Form |
Lyophilized powder, sealed under argon |
| Storage |
−20°C (long-term) |
| Documentation |
Batch-specific COA (HPLC + Mass Spec) |
Storage & Handling (Research Laboratories)
Lyophilized Tesamorelin should be stored at −20°C for long-term preservation, protected from light and moisture. For short-term active research use, 4°C storage is acceptable for up to approximately 4 weeks. Minimize repeated freeze-thaw cycles. Follow standard laboratory peptide reconstitution and handling protocols for all experimental use.
Frequently Asked Questions — Tesamorelin Research
Why is Tesamorelin unique among GHRH analogs?
Tesamorelin is notable for several reasons that distinguish it from other GHRH analogs: (1) It uses the complete 44-amino-acid GHRH sequence rather than the truncated 29-amino-acid fragment used by Sermorelin and CJC-1295; (2) Its trans-3-hexenoic acid N-terminal modification confers DPP-IV resistance while maintaining the full GHRH sequence; (3) It is the only GHRH analog to receive FDA approval (for HIV lipodystrophy in 2010); and (4) It has extensive randomized clinical trial data published in major journals, providing a uniquely well-characterized pharmacological profile compared to other GHRH analogs.
What FDA-approved indication does Tesamorelin have and what were the trial results?
Tesamorelin (Egrifta) was FDA-approved in 2010 for the reduction of excess abdominal fat associated with HIV-related lipodystrophy in HIV-infected adults. Phase III trials (PERCEIVED and TRIMM studies published in NEJM and other journals) demonstrated approximately 15-18% reduction in visceral adipose tissue (measured by CT scan) compared to placebo after 26 weeks of daily subcutaneous administration, with concurrent improvements in triglyceride levels. These trials enrolled over 800 HIV-infected subjects and established the safety and efficacy profile used in FDA approval.
What cognitive research has been conducted with Tesamorelin?
Several randomized trials led by Lisa Baker and colleagues at the University of Wisconsin examined Tesamorelin’s effects on cognitive function. A published trial in JAMA Neurology (2020) found that 20 weeks of Tesamorelin administration improved verbal memory (Rey Auditory Verbal Learning Test) and visuospatial learning in older adults without HIV compared to placebo, with particular benefit in subjects with mild cognitive impairment risk factors. Research has also examined Tesamorelin in HIV-associated neurocognitive disorder (HAND). These findings suggest GH/IGF-1 axis modulation may influence cognitive outcomes in specific populations.
Is Tesamorelin available for human use?
Tesamorelin (Egrifta/Egrifta SV) is FDA-approved and available by prescription in the US specifically for HIV lipodystrophy. Research Peptides Supplies supplies Tesamorelin as a research-grade peptide for qualified laboratory research use only, separate from any clinical or prescription context.
What documentation comes with Tesamorelin?
Tesamorelin from Research Peptides Supplies is verified at ≥98% purity by HPLC with identity confirmed by Mass Spectrometry. A batch-specific COA with lot number, purity data, mass verification, and testing methodology is provided with every order.
⚗️ Research Use Only: This product is strictly intended for qualified laboratory and scientific research use by trained professionals in appropriate laboratory settings. It is not intended for human or veterinary administration, therapeutic use, food supplement applications, or any use outside controlled research environments. Not for human consumption.
